PMID- 38150890
OWN - NLM
STAT- MEDLINE
DCOM- 20240220
LR  - 20240321
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Linking)
VI  - 387
DP  - 2024 Feb 15
TI  - Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and 
      initial short-term glucocorticoids efficacy in myasthenia gravis patients.
PG  - 578269
LID - S0165-5728(23)00255-2 [pii]
LID - 10.1016/j.jneuroim.2023.578269 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory agent involved 
      in various autoimmune and inflammatory diseases including myasthenia gravis (MG). 
      In this study, we enrolled 409 adult MG patients and 487 healthy individuals to 
      investigate the association between TNF-alpha polymorphism and MG. We found the 
      rs1800629 A allele frequency was significantly higher in the MG group than in the 
      control group. Subgroup analysis revealed that the A allele frequencies were 
      significantly higher in the early-onset subgroup, non-thymoma subgroup, 
      ocular-onset subgroup, and mild severity subgroup than in the control group. To 
      minimize the interactions between clinical features, we used a comprehensive 
      classification and found that the rs1800629 A allele frequency was significantly 
      higher in the non-thymoma AChR-Ab negative subgroup than in the control group. In 
      the analysis of initial short-term glucocorticoids (GC) efficacy in the 
      treatment-naive patients, the rs1800629 A allele frequency was significantly 
      higher in the unresponsive subgroup than in the responsive group and the control 
      group. Logistic regression demonstrated the rs1800629 genotypes in the dominant 
      model and disease duration prior to GC treatment independently contributed to 
      initial short-term GC efficacy. In conclusion, our study revealed that in Chinese 
      adult MG patients, rs1800629 polymorphism in TNF-alpha was associated with the 
      susceptibility of MG and might indicate the initial short-term GC efficacy.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Li, Hong-Yan
AU  - Li HY
AD  - Department of Neurology, Qilu Hospital of Shandong University, 107 Wenhua West 
      Road, Jinan 250012, China.
FAU - Xia, Meng
AU  - Xia M
AD  - School Hospital, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
FAU - Song, Min
AU  - Song M
AD  - Department of Neurology, Qilu Hospital (Qingdao) of Shandong University, 758 
      Hefei Road, Qingdao 266035, China.
FAU - Xie, Yanchen
AU  - Xie Y
AD  - Department of Neurology, Beijing Friendship Hospital, Capital Medical University, 
      95 Yongan Road, Xicheng District, Beijing 100050, China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Neurology, Affiliated Hospital of Qingdao University, 16 Jiangsu 
      Road, Qingdao 266003, China.
FAU - Yue, Yao-Xian
AU  - Yue YX
AD  - Department of Neurology, Qilu Hospital of Shandong University, 107 Wenhua West 
      Road, Jinan 250012, China. Electronic address: yyx12550@163.com.
FAU - Li, Hai-Feng
AU  - Li HF
AD  - Department of Neurology, Qilu Hospital of Shandong University, 107 Wenhua West 
      Road, Jinan 250012, China. Electronic address: drlhf@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231220
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Glucocorticoids)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (TNF protein, human)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Genetic Predisposition to Disease/genetics
MH  - Genotype
MH  - Glucocorticoids/therapeutic use
MH  - *Myasthenia Gravis/drug therapy/genetics
MH  - Polymorphism, Single Nucleotide/genetics
MH  - *Tumor Necrosis Factor-alpha/genetics
OTO - NOTNLM
OT  - Glucocorticoid efficacy
OT  - Myasthenia gravis
OT  - Polymorphism
OT  - Susceptibility
OT  - Tumor necrosis factor-alpha
COIS- Declaration of Competing Interest The authors declare no conflict of interest.
EDAT- 2023/12/28 00:42
MHDA- 2024/02/11 07:42
CRDT- 2023/12/27 18:09
PHST- 2023/10/15 00:00 [received]
PHST- 2023/11/30 00:00 [revised]
PHST- 2023/12/17 00:00 [accepted]
PHST- 2024/02/11 07:42 [medline]
PHST- 2023/12/28 00:42 [pubmed]
PHST- 2023/12/27 18:09 [entrez]
AID - S0165-5728(23)00255-2 [pii]
AID - 10.1016/j.jneuroim.2023.578269 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2024 Feb 15;387:578269. doi: 10.1016/j.jneuroim.2023.578269. Epub 
      2023 Dec 20.